Table 1 The roles of RNA methylation modification in gliomas
From: Insights into the regulatory role of RNA methylation modifications in glioma
Modification regulators | Roles | Expression | Target or related pathway | Related biological characters | Refs |
|---|---|---|---|---|---|
m6A | |||||
Writer | |||||
METTL3 | Oncogene | Upregulated | SOX2 | Tumor growth | [20] |
MGMT、ANPG | Drug resistance | [21] | |||
ADAR、APOBEC3A | RNA processing and Cancer-related pathways | [22] | |||
SRSF | Tumor growth and progression | [24] | |||
UBXN1 | Tumor progression | [66] | |||
Tumor suppressor | Downregulated | – | Growth and renewal of GSCs | [27] | |
circDLC1 | Proliferation | [156] | |||
PI3K/Akt、COL4A1、HSP90 | Proliferation、invasion and migration of cancer cell | ||||
METTL14 | Tumor suppressor | Upregulated or downregulated | – | Disturbance of oncogene and anti-oncogene expression | [27] |
ASS1 | Proliferation、growth、invasion and migration of cancer cell | [31] | |||
WTAP | Oncogene | Upregulated | – | Associated with prognosis | |
RBM15/15B | – | Upregulated | – | Related to grade of gliomas and drug resistance | |
KIAA1429/VIRMA | – | Upregulated and downregulated in GBMs com- paring with LGGs | Tumor procedure | [159] | |
ZC3H13 | – | Downregulated | – | Drug resistance | |
Eraser | |||||
FTO | Oncogene | Upregulated | MYC-miR-155/23a Cluster-MXI1 | Drug resistance | [45] |
– | Growth of GSC | [27] | |||
PDK1 | Aerobic glycolysis of cancer cell | [46] | |||
Tumor suppressor | Downregulated | FOXO3a | Poor prognosis and malignant tumor behavior | ||
ALKBH5 | Tumor suppressor | Upregulated | G6PD mRNA | Proliferation and metabolism of cancer cell | [54] |
– | Epithelial-mesenchymal transition and vasculogenic mimicry | [55] | |||
NANOG | Drug resistance | [56] | |||
Homologous recombination (CHK1、RAD51) | Resistance to radiation | [57] | |||
SOX2 | Proliferation、apoptosis and drug resistance of cancer cell | [58] | |||
FOXM1 | Proliferation and renewal of cancer cell | [59] | |||
Reader | |||||
YTHDF1 | Oncogene | Upregulated | MSI1 | Proliferation、invasion and chemoresistance of gliomas | [69] |
YTHDF2 | Oncogene | Upregulated | LXRα and HIVEP2 | Proliferation and invasion of gliomas | [65] |
– | Grade of gliomas and prognosis | [66] | |||
UBXN1 | Progression of gliomas | [66] | |||
YTHDC1 | Oncogene | – | VPS25 | Proliferation of cancer cell | [161] |
W377A/W428A mutants | Function of cancer cell | [24] | |||
YTHDC2 | – | Upregulated and downregulated in GBMs com- paring with LGGs | – | Prognosis of low-grade gliomas | [73] |
IGF2BP1 | Oncogene | Upregulated | Lnc00689/ miR-526b-3p/IGF2BP1 | Tumorigenesis | [72] |
IGF2BP2 | Oncogene | Upregulated | lncRNA OIP5-AS1/miRNA-4950-3p | Tumorigenesis and vasculogenic mimicry | [77] |
IGF2BP2/lncRNA FBXL19-AS1/ZNF765 | Chemoresistance | [78] | |||
HNRNP | Oncogene | Upregulated and downregulated in GBMs com- paring with LGGs | AKT and STAT3 signal pathway | Biological behavior of tumor | [87] |
eIF3 | Oncogene | Downregulated | Cell cycle and apoptosis | [95] | |
m5C | |||||
Writer | |||||
NSUN2 | – | Upregulated | ATX | Cell cycle and migration | [105] |
NSUN5 | – | Downregulated | rRNA | stress survival adaptations | |
Eraser | |||||
TET1 | Tumor suppressor | Upregulated | - | Repair of DNA damage | |
Reader | |||||
YBX1 (YB-1) | Oncogene | Upregulated | ErbB, mTOR, HIF-1, cGM PKG, insulin signal pathway | Tumorigenesis and epithelial-mesenchymal transition | [123] |
YB-1 / CCT4 / mLST8 / mTOR | Tumor growth | [163] | |||
ALYREF | – | Upregulated | – | Prognosis factor | [125] |
m7G | |||||
Writer | |||||
METTL1/ WDR4 | Oncogene | Upregulated | MAPK signal pathway | Related to the grade and progression of gliomas | |
RNMT/ RAM | Oncogene | Upregulated | B7-H6/c-myc | Proliferation of GSCs | [141] |
WBSCR22/TRMT112 | Oncogene | Upregulated | PI3K/AKT/GSK3β signal pathway | Growth and metastasis of gliomas cell | [143] |